Clinical trials using the MEK inhibitor, selumetinib, revealed decreased pNF and spinal neurofibroma burden (Jackson et al., 2020) with minimal side effects (Baldo et al., 2021), and another MEK inhibitor, trametinib, decreased tumor size (Toledano et al., 2021; Weiss et al., 2021). Here, MAP2K7 is linked to plexiform neurofibroma.